Cargando…
Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a type of blood cancer characterized by the uncontrolled clonal proliferation of myeloid hematopoietic progenitor cells in the bone marrow. The outcome of AML is poor, with five-year overall survival rates of less than 10% for the predominant group of patients older t...
Autores principales: | Van Acker, Heleen H., Versteven, Maarten, Lichtenegger, Felix S., Roex, Gils, Campillo-Davo, Diana, Lion, Eva, Subklewe, Marion, Van Tendeloo, Viggo F., Berneman, Zwi N., Anguille, Sébastien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572115/ https://www.ncbi.nlm.nih.gov/pubmed/31035598 http://dx.doi.org/10.3390/jcm8050579 |
Ejemplares similares
-
The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy
por: Campillo-Davo, Diana, et al.
Publicado: (2021) -
Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA
por: Campillo-Davo, Diana, et al.
Publicado: (2020) -
Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
por: Timmers, Marijke, et al.
Publicado: (2019) -
Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy
por: Van Acker, Heleen H, et al.
Publicado: (2015) -
Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands
por: Versteven, Maarten, et al.
Publicado: (2022)